Sanofi Posts More Positive Olipudase Alfa Data As Approval Decisions Loom

First Potential Therapy For Rare Lysosomal Storage Disease

Ahead of a PDUFA date of 3 July, Sanofi has added to the body of clinical evidence supporting olipudase alfa as a treatment for acid sphingomyelinase deficiency (ASMD), a rare, progressive and potentially life-threatening disease with no approved therapies.

Paperwork
Sanofi amasses more data on olipudase alfa • Source: Alamy

As it awaits approvals on both sides of the Atlantic and in Japan for olipudase alfa, Sanofi has trumpeted more positive data on what could soon be the first therapy for acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease.

The French major has presented results at the lyso

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip